Table II: Top 50 pharmaceutical companies (Rankings 31–40)

Sanofi-Aventis. Sanofi-Aventis made no major asset disposals in 2007, and its principal investments were by its vaccine subsidiary, Sanofi Pasteur (Lyon, France). In 2007, Sanofi Pasteur increased the capacity of its Lyon manufacturing facility by 4800 m² . Sanofi Pasteur is constructing a formulation-and-filling facility in Val de Reuil, France, to boost filling capabilities, mainly for influenza vaccines. In 2007, Sanofi completed the construction of a new $150-million, 140,000-ft² influenza vaccine-manufacturing facility in Swiftwater, Pennsylvania. The new facility doubles the site's capacity to more than 100 million doses of influenza vaccine per year. The facility is projected to come on line in late 2008 or early 2009, following licensing by the US Food and Drug Administration. Sanofi also was awarded a $77.4-million contract by the US Department of Health and Human Services (HHS) to retrofit its existing influenza vaccine-manufacturing facility to switch to pandemic vaccine manufacture at HHS's request. Sanofi Pasteur is contributing $25 million to the project. The retrofit is scheduled to begin when the company's new influenza vaccine-manufacturing facility is licensed by FDA and is operational. Sanofi is building an influenza vaccine-manufacturing facility in Shenzhen, China. The facility will produce pandemic influenza vaccine and is scheduled to be completed and operational by 2012. Sanofi is further investing C$100 million ($98 million) in a 165,000-ft² vaccine R&D facility in Toronto, which is scheduled for occupancy in 2010.

In December 2007, Sanofi-Aventis opened a 2600-m² center in Goa, India, for analytical and formulation development. The facility is the company's first pharmaceutical-development center in Asia and its single largest investment in India to date.